Abstract: The present invention concerns novel paclitaxel derivatives, their use as antitumor agents, and pharmaceutical formulations.

Abstract: A process for the preparation of the enol lactone of 2-oxocyclohexylidene acetic acid wherein(i) glyoxylic acid is allowed to react with cyclohexanone in the presence of a halogen acid in order to obtain a crude reaction product B1, then(ii) said crude reaction product B1 is allowed to react, after solubilisation in an organic solvent, in the presence of a strong acid soluble in said organic solvent or of strongly acid resins, in order to obtain the enol lactone of 2-oxocyclohexylidene acetic acid which is isolated if desired,and application to the preparation of 2-coumaranone.

Abstract: An efficient protocol for the synthesis of taxol, taxol analogs and their intermediates is described. The process incudes the attachment of the taxol A-ring side chain to baccatin III and for the synthesis of taxol and taxol analogs with variable A-ring side chain structures. A rapid and highly efficient esterification of O-protected isoserine and 3-phenylisoserine acids having N-benzyoloxycarbonyl groups to the C-13 hydroxyl of 7-O-protected baccatin III is followed by a deprotection-acylation sequence to make taxol, celphalomanninne and various analogs, including photoaffinity labeling candidates.

Abstract: A taxoid derivative wherein sugar is combined with any one of paclitaxel, docetaxel and 10-deacetyl-bacatin III via a spacer. A method of producing the taxoid derivative comprises protecting hydroxyl groups at specific position of paclitaxel or docetaxel by protective compound followed by reacting with tetrabenzyl acetyloxyglucoside, and then carrying out debenzyl and detriethylsilyl reactions. A method of producing the taxoid derivative comprises reacting paclitaxel or docetaxel with tetrabenzyl acetyloxyglucoside, and then carrying out debenzyl reaction.

Abstract: A novel taxol derivative having the formula (I), in which the 10-position is modified to have a carbon-carbon bond, is disclosed. The taxol derivative of the present invention has an antitumor activity.

Abstract: A process of making taxane derivatives by reacting Baccatin III derivatives with an oxazolidine which contains a thioester substituent at the 4-position.

Abstract: Propylene is oxidized to propylene oxide in the vapor phase using an oxygen-containing gas and a supported silver catalyst comprising silver and a support comprised in whole or in substantial part of certain alkaline earth metal compounds. The alkaline earth metal compound may, for example, be a calcium compound such as calcium titanate, tribasic calcium phosphate, calcium molybdate, or calcium fluoride, a magnesium compound such as magnesium aluminate, or a strontium compound such as strontium titanate. Such supports provide significantly higher selectivity to the desired epoxide than would be expected from the performance of related materials. Propylene oxide selectivity may be further enhanced through the introduction of nitrogen oxide species such as NO, alkyl halides such as ethyl chloride, and carbon dioxide into the oxygen-containing gas.

Abstract: Novel taxane derivatives and intermediates having the formula 1. ##STR1## and a process for the preparation of the compounds of the formula 1 from 14-.beta.-hydroxy-10-deacetylbaccatin III of formula 2 ##STR2## and pharmaceutically acceptable compositions containing the taxane derivatives and intermediates of formula 1.

Abstract: A method of promoting drainage of mucous secretions in the congested airways of a bedridden/immobilized patient or an intubated/mechanically-ventilated patient is disclosed. The method comprises administering to the airways of the patient a uridine phosphate such as uridine 5'-triphosphate (UTP) or P.sup.1,P.sup.4 -di(uridine-5')tetraphosphate, an analog of UTP, or any other analog, in an amount effective to promote drainage of fluid in the congested airways, including sinuses, by hydrating mucous secretions or by stimulating ciliary beat frequency in the airways. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include any liquid suspension (including nasal drops or eye drops or spray), oral form (liquid or pill), aerosol inhalation, powder form, topical, injected, intra-operative instillation or suppository form.

Abstract: Process for the synthesis of taxol and other tricyclic and tetracyclic taxanes.

Abstract: A process for the preparation of taxol and derivatives of taxol ##STR1## is disclosed. The process involves reacting a .beta.-alkoxycarbonylamino-phenylpropionic acid with a 13-hydroxy taxane to produce an ester of the taxane at C-13; and then deprotecting the .beta.-alkoxycarbonylamino-phenylpropionic ester to produce a .beta.-amido-.alpha.-hydroxybenzenepropanoic ester of the taxane. Intermediates useful in the process are also disclosed.

Abstract: Bioactive ABC taxoids accessible by convergent synthesis have an intact AB ring framework of taxol, including the C.sup.13 side chain, and an aromatic C ring which substitutes for the CD ring system found on native taxol. The aromatic C ring may be substituted or unsubstituted. MPT derivatives of ABC taxoids are also disclosed.

Abstract: A paclitaxel prodrug has a paclitaxel portion coupled to a cleavable N-(aliphatic or aromatic)-O-glycosyl carbamate spacer group, and can be administered orally, topically or by injection to provide an anti-tumor effect, the prodrug being activated by a hydrolizing enzyme, an endogeneous enzyme or an exogeneous enzyme.

Abstract: Oxirane compounds are produced by molecular oxygen oxidation of an olefin in the presence of a nitrogen oxide catalyst.

Abstract: The substituted 4H-pyrans are prepared by reacting either aldehydes or ylidene compounds with suitably substituted .beta.-diketones. The substituted 4H-pyrans according to the invention are suitable as active compounds in medicaments, in particular for the treatment of disorders of the central nervous system.

Abstract: Pyridyl substituted .beta.-lactam compounds used in preparing taxane derivatives having a 3' pyridyl substituted C13 side chain.

Abstract: A biotransformation process for the production of hydroxylated derivatives of taxol and new derivatives of taxol and cephalomannine are described. A method for converting taxol to L-760,006 and L-760,007, and a method for converting cephalomanine to L-745,596 are provided.

Abstract: The present invention relates to novel derivatives obtained by oxidation and the stereospecific reduction of 10-deacetylbaccatine III, and successive esterification with a variously substituted isoserine chain to prepare taxol analogues. The products of the invention have cytotoxic and anti-tumoural activities and, when suitably formulated, can be administered by injection and/or orally.

Abstract: This invention relates to a process for the preparation of 7-hydroxy taxanes of general formula (I) from 7-trialkylsilyl taxanes of general formula (II), wherein R.sub.1 is hydrogen, alkoxy, acyloxy, or alkoxyacetoxy, and Z is a hydrogen atom or a radical of general formula (III), wherein R.sub.2 is an optionally substituted benzyl radical or an R'.sub.2 --O--CO-- radical wherein R'.sub.2 is an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, bicycloalkyl, optionally substituted phenyl or heterocyclyl radical, R.sub.3 is an aromatic alkyl, alkenyl, alkynyl, cycloalyl, phenyl, naphthyl or heterocyclyl radical and either R.sub.4 is a hydrogen atom and R.sub.5 is a hydroxyl function protecting group, or R.sub.4 and R.sub.5 together form a saturated 5- or 6-membered heterocylic ring. In general formula (II), each R, which are the same or different, is an alkyl radical optionally substituted by a phenyl radical.

Abstract: A method of acylating 10-deacetylbaccatin III at the C-10 position over the C-7 hydroxy position thereof to produce baccatin III is accomplished first by dissolving 10-deacetylbaccatin III in an anhydrous ether solvent, such as tetrahydrofuran, at a reduced temperature, preferably -78.degree. C. At least an equivalent of a lithium base, preferably about two equivalents n-butyl lithium, is next added followed by the addition of an acylating agent, such as acetyl chloride. The resulting solution is quenched, for example with ammonium chloride, to eliminate excess of the lithium base and the acylating agent. The result is baccatin III in solution. The baccatin III may be recovered by removing the ether solvent under vacuum to produce a residue that may then be dissolved, for example in ethyl acetate, with this solution being washed to remove unwanted salt compounds. Recrystallization and column chromatography may be employed to purify the baccatin III.